FDA Grants Regenerative Medicine Designation to Humacyte Vascular Tissue Therapy

Drug Industry Daily
A A
The FDA granted expedited review to Humacyte’s tissue therapy under the new Regenerative Medicine Advanced Therapy pathway — one of the first products to receive the designation established by the 21st Century Cures Act.

To View This Article:

Login

Subscribe To Drug Industry Daily